Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
Processing and Reporting of Breast Specimens in the Neoadjuvant Setting. Surg Pathol Clin. 2018 Mar;11(1):213-230 Authors: Bossuyt V Abstract Standardization of quantification of residual disease in the breast and lymph nodes with routine pathologic macroscopic and microscopic evaluation leads to accurate and reproducible measures of response to neoadjuvant treatment. Multidisciplinary collaboration and correlation of clinical, imaging, gross and microscopic findings is essential. The processing approach to post-neoadjuvant breast cancer surgical specimens and the elements needed in the pathology report are the same regardless of breast cancer subtype or type of neoadjuvant treatment. The residual cancer burden incorporates response in the breast and in the lymph nodes into a score that can be combined with other emerging prognostic factors. PMID: 29413658 [PubMed - in process]
Condition: Breast Cancer Triple Negative Intervention: Drug: Goserelin Sponsor: Kasr El Aini Hospital Not yet recruiting
ConclusionsNeoadjuvant versus adjuvant with standard anthracycline- and taxane-containing regimens results in similar disease-free survival and overall survival among patients with stage I and II triple-negative breast cancer regardless of BRCA status. Further studies are needed to evaluate whether similar results are observed with newer agents.
ConclusionAlthough the study was terminated owing to the altered liver function, it showed that there was a trend to greater shrinkage of tumor in the combination group for ER-positive, HER2-negative postmenopausal breast cancer.
ConclusionThe presence of microcalcifications on imaging and DCIS on initial CNB are associated with residual disease after neoadjuvant chemotherapy in TNBC. These variables can aid in identifying patients with TNBC suitable for inclusion in trials evaluating non‐surgical management after neoadjuvant chemotherapy.
CONCLUSION: The presence of microcalcifications on imaging and DCIS on initial CNB are associated with residual disease after neoadjuvant chemotherapy in TNBC. These variables can aid in identifying patients with TNBC suitable for inclusion in trials evaluating non-surgical management after neoadjuvant chemotherapy. PMID: 29465744 [PubMed - as supplied by publisher]
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent adverse reaction caused by chemotherapeutic agents, especially the taxanes. CIPN can persist from months to years after completion of chemotherapy, decreasing quality of life for cancer survivors. The aim of this study was to explore the incidence and risk factors of persistent CIPN among women with breast cancer receiving neoadjuvant chemotherapy.
CONCLUSIONS: we identified capecitabine as efficient chemotherapy in TNBC PDX models established from residual disease and resistant to anthracyclines, taxanes and platins. RB positivity and high expression of TYMP were significantly associated with capecitabine response. PMID: 29463559 [PubMed - as supplied by publisher]
This article reviews the impact of MR imaging in different settings on medical oncology decision-making in patients with breast cancer.
Contributors : Nicolai J Birkbak ; Andrea L RichardsonSeries Type : Expression profiling by arrayOrganism : Homo sapiensGene expression data from 21 triple negative breast cancer samples treated with cisplatin&bevacizumab in the neoadjuvant setting as part of a clinical trial.Gene expression data RMA normalized was used to find predictors of platinum sensitivity